Delcath

DCTH

14.7000.41% ( -0.060 )

Closed: Oct 21, 16:00:00 (EDT)

Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus estimates across top and bottom lines: revenue reached $29.1M vs. $26.3M expected, while Diluted EPS (GAAP) of $0.07 beat the expected -$0.09 loss. Performance was driven by a 30% YoY volume surge in HEPZATO procedures and expanded gross margins of 90%. Management raised FY2026 revenue guidance to $104M-$108M, signaling robust demand for interventional oncology solutions.

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Delcath(DCTH) the Revenue is 29.13 M (+20.6%), Beat estimate;the EBIT is 2.395 M (-7.53%), Beat estimate;the EPS is 0.07 (+0%), Beat estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

RevenueExceed expectations

0.03B20.60%

0.03B8.71%

+0.00B11.89%

EBITExceed expectations

0.00B7.53%

-0.00B257.81%

+0.01B250.28%

EPSExceed expectations

0.07--

-0.09228.57%

+0.1600228.57%

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly